A person standing beside a Deloitte office sign

Here's the lowdown

  • Deloitte will stop covering GLP-1 medications when they are prescribed for weight loss.

  • Employees will also face higher deductibles and out-of-pocket maximums under most of the firm's U.S. health plans.

  • The move follows a similar cut at PwC and a wider retreat from employer coverage as drug and insurance costs rise.

Deloitte's GLP-1 weight-loss coverage is going away, and the fight over these drugs just landed inside the firm's benefits package.

The Big Four firm will stop covering GLP-1 medications when they are prescribed for weight loss. The change is limited to that use, but it could still leave some employees with a much larger monthly bill.

Deloitte is not making just one cut. Its internal benefits guide also shows higher deductibles and out-of-pocket maximums under most health plans. In plain English, workers may pay more before insurance starts helping and more before their annual spending cap kicks in.

Why Deloitte is pulling back

GLP-1 drugs have become one of the fastest-growing costs in employer health plans. They can be highly effective, but long-term treatment can be expensive when thousands of employees are eligible.

Deloitte told staff that the changes reflect hard trade-offs in the current cost environment. The firm said some expenses had become too large for it to carry alone.

Here's the thing. The firm is shifting part of a fast-rising health bill back to employees.

This is bigger than one Big Four firm

PwC made a similar coverage change earlier this year. And the pullback now reaches far beyond accounting.

Many large employers are dropping or narrowing GLP-1 coverage as they build 2027 health plans. Higher premiums are already squeezing benefits budgets, and weight-loss drugs add another costly line item.

Employers now face an awkward choice. Cover the drugs and absorb a bigger bill, or cut coverage and risk making a popular benefit feel much less generous.

The savings come with a people problem

For employees, the line between weight loss and medical care is not always neat. Obesity can overlap with insulin resistance, heart risk and other chronic conditions. A plan may call the drug a weight-loss benefit while the person taking it sees long-term treatment prescribed by a doctor.

That gap is where the backlash will live. A cost-control decision on a spreadsheet can feel like a pay cut to the employee who now has to fund the medication alone.

Deloitte may lower its near-term pharmacy bill. But the firm will also find out how much workers valued the coverage when open enrollment begins.

The next question is whether other major accounting firms follow. Watch the 2027 open-enrollment guides. Once one large employer trims an expensive benefit, rivals suddenly have cover to do the same.

Keep Reading


View More >